TrialStudy of AT-752 in Patients With Dengue Infection
Trial details
- Registry ID
- NCT05466240
- Phase
- Phase 2
AVIR
Atea Pharmaceuticals, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
5Trials in this database
4Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of AT-752 in Patients With Dengue InfectionNCT05466240 | AVIR | Phase 2 | Terminated | 2023-01-19Actual |
| SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19NCT05629962 | AVIR | Phase 3 | Completed | 2024-04-25Actual |
| A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCVNCT05904470 | AVIR | Phase 2 | Completed | 2024-12-09Actual |
| C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCVNCT06868264 | AVIR | Phase 3 | Active not recruiting | 2026-09Estimated |
| C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCVNCT07037277 | AVIR | Phase 3 | Active not recruiting | 2026-12Estimated |
SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
Trial details
- Registry ID
- NCT05629962
- Phase
- Phase 3
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
Trial details
- Registry ID
- NCT05904470
- Phase
- Phase 2
C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
Trial details
- Registry ID
- NCT06868264
- Phase
- Phase 3
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
Trial details
- Registry ID
- NCT07037277
- Phase
- Phase 3
Latest recorded trial changes
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
NCT07037277 · Atea Pharmaceuticals, Inc.
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
NCT06868264 · Atea Pharmaceuticals, Inc.
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
NCT05904470 · Atea Pharmaceuticals, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Proportion of Subjects Achieving Sustained Virologic Response at 12 Weeks Post-treatment (SVR12)
+ After
Measure: Percentage of Subjects Achieving Sustained Virologic Response at 12 Weeks Post-treatment (SVR12)
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
NCT05904470 · Atea Pharmaceuticals, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Proportion of subjects experiencing treatment-emergent adverse events
Measure: Proportion of subjects achieving sustained virologic response at 12 weeks post-treatment (SVR12)
+ After
Measure: Proportion of Subjects Achieving Sustained Virologic Response at 12 Weeks Post-treatment (SVR12)